日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Immunogenicity and safety of biological E's 14-valent pneumococcal conjugate vaccine (PNEUBEVAX 14®) administered in a 2p + 1 schedule to healthy infants: a multicenter, randomized, active controlled, single-blind, phase III trial

一项多中心、随机、活性对照、单盲、III期临床试验，旨在评估生物制品公司E研发的14价肺炎球菌结合疫苗（PNEUBEVAX 14®）在健康婴儿中采用2p+1接种程序时的免疫原性和安全性。

期刊:Lancet Regional Health - Southeast Asia
影响因子:6.2
doi:10.1016/j.lansea.2026.100746
Thuluva, Subhash; Matur, Ramesh V; Gunneri, Subbareddy; Ningaiah, Siddalingaiah; Yerroju, Vijay; Mogulla, Rammohan Reddy; Dhar, Chirag; Thammireddy, Kamal; Paliwal, Piyush; Kawade, Anand; Nanjappa, Pradeep; Pramod, Jog; Narang, Manish; Chakravarthy, Bheemisetty S; Virupakashappa, Prashanth M
肺炎
免疫/内分泌
发表日期：2026
文献求助 收藏

Immunogenicity and Safety of Biological E's Monovalent rDNA Hepatitis B Vaccine (BEVAC(®)) in Neonates and Infants: A Multicentre, Randomized, Phase IV Non-Inferiority Trial

Biological E公司单价重组DNA乙型肝炎疫苗（BEVAC®）在新生儿和婴儿中的免疫原性和安全性：一项多中心、随机、IV期非劣效性试验

期刊:Viruses-Basel
影响因子:3.5
doi:10.3390/v18040472
Thuluva, Subhash; Gunneri, Subbareddy; Ningaiah, Siddalingaiah; Yerroju, Vijay; Mogulla, Rammohan Reddy; Dhar, Chirag; Thammireddy, Kamal; Esanakarra, Raju; Nanjappa, Pradeep; Mahantshetti, Niranjana S
免疫/内分泌
肝炎
发表日期：2026
文献求助 收藏

Corrigendum to 'Immunogenicity and safety of Biological E's CORBEVAX™ vaccine as a heterologous booster dose in adult volunteers previously vaccinated with two doses of either COVISHIELD™ or COVAXIN: A Prospective double-blind randomised phase III clinical study' [IJID Regions, volume 17 (2025) 100786]

对“Biological E 的 CORBEVAX™ 疫苗作为异源加强剂量在先前接种过两剂 COVISHIELD™ 或 COVAXIN 的成年志愿者中的免疫原性和安全性：一项前瞻性双盲随机 III 期临床研究”的更正 [IJID Regions，第 17 卷（2025 年）100786]

期刊:IJID Regions
影响因子:1.7
doi:10.1016/j.ijregi.2025.100831
Thuluva, Subhash; Paradkar, Vikram; Gunneri, SubbaReddy; Yerroju, Vijay; Mogulla, Rammohan Reddy; Thammireddy, Kamal; Ningaiah, Siddalingaiah; Dhar, Chirag; Binayke, Akshay; Zaheer, Aymaan; Awasthi, Amit; Narang, Shiva; Reddy, Naveen Chander; Pandey, Anil Kumar; Anjaneylu, Chitta Sitaram
免疫/内分泌
发表日期：2026
文献求助 收藏

Safety and immunogenicity of booster doses of an XBB.1.5 RBD subunit COVID-19 vaccine among individuals aged 5-80 years in India: a phase 3, single-blind, randomised controlled trial

在印度5-80岁人群中，XBB.1.5 RBD亚单位COVID-19疫苗加强剂量的安全性和免疫原性：一项3期单盲随机对照试验

期刊:Lancet Regional Health - Southeast Asia
影响因子:6.2
doi:10.1016/j.lansea.2025.100642
Thuluva, Subhash; Paradkar, Vikram; Gunneri, SubbaReddy; Mogulla, Rammohan Reddy; Yerroju, Vijay; Dhar, Chirag; Ningaiah, Siddalingaiah; Panchakshari, Mallikarjuna; Gillurkar, Chandrashekhar S; Narang, Manish; Kisan, Shivnitwar Sachin; Rao, A Venkateshwar
免疫/内分泌
发表日期：2025
文献求助 收藏

Beyond immunogenicity in XBB.1.5 subunit COVID-19 boosters focusing on durability, dosing, and target populations: authors reply

除了XBB.1.5亚单位COVID-19加强针的免疫原性之外，还应关注其持久性、剂量和目标人群：作者回复

期刊:Lancet Regional Health - Southeast Asia
影响因子:6.2
doi:10.1016/j.lansea.2025.100678
Thuluva, Subhash; Paradkar, Vikram; Gunneri, SubbaReddy; Mogulla, Rammohan Reddy; Yerroju, Vijay; Ningaiah, Siddalingaiah; Panchakshari, Mallikarjuna; Dhar, Chirag
免疫/内分泌
发表日期：2025
文献求助 收藏

Immunogenicity and safety of a multi-human dose formulation of Biological E's 14-valent pneumococcal polysaccharide conjugate vaccine (PNEUBEVAX 14(®)) administered to 6-8-week-old healthy infants: a phase 3, single-blind, randomized, active-controlled study

一项针对6-8周龄健康婴儿的3期单盲、随机、活性对照研究，评估了Biological E公司14价肺炎球菌多糖结合疫苗（PNEUBEVAX 14®）多剂量制剂的免疫原性和安全性。

期刊:Frontiers in Immunology
影响因子:5.9
doi:10.3389/fimmu.2025.1550227
Thuluva, Subhash; Matur, Ramesh V; Gunneri, Subbareddy; Mogulla, Rammohan Reddy; Thammireddy, Kamal; Peta, Kalyan Kumar; Paliwal, Piyush; Mahantshetti, Niranjana S; Banala, Ramesh Kumar; Siddaiah, Prashanth
肺炎
免疫/内分泌
发表日期：2025
文献求助 收藏

Immunogenicity and safety of Biological E's CORBEVAX™ vaccine as a heterologous booster dose in adult volunteers previously vaccinated with two doses of either COVISHIELD™ or COVAXIN: A prospective double-blind randomized phase III clinical study

Biological E 公司的 CORBEVAX™ 疫苗作为异源加强剂在先前接种过两剂 COVISHIELD™ 或 COVAXIN 疫苗的成年志愿者中的免疫原性和安全性：一项前瞻性双盲随机 III 期临床研究

期刊:IJID Regions
影响因子:1.7
doi:10.1016/j.ijregi.2025.100786
Thuluva, Subhash; Paradkar, Vikram; Gunneri, SubbaReddy; Yerroju, Vijay; Mogulla, Rammohan Reddy; Thammireddy, Kamal; Ningaiah, Siddalingaiah; Dhar, Chirag; Binayke, Akshay; Zaheer, Aymaan; Awasthi, Amit; Narang, Shiva; Reddy, Naveen Chander; Pandey, Anil Kumar; Anjaneylu, Chitta Sitaram
免疫/内分泌
发表日期：2025
文献求助 收藏

Safety and immunogenicity of Biological E's typhoid conjugate vaccine TYPHIBEV(Ⓡ) concomitantly administered with measles rubella vaccine: a phase IV prospective, multicenter study

Biological E公司伤寒结合疫苗TYPHIBEV®与麻疹风疹疫苗同时接种的安全性和免疫原性：一项IV期前瞻性多中心研究

期刊:IJID Regions
影响因子:1.7
doi:10.1016/j.ijregi.2025.100611
Thuluva, Subhash; Matur, Ramesh V; Gunneri, SubbaReddy; Mogulla, Rammohanreddy; Dhar, Chirag; Yerroju, Vijay; Balne, Nagaganesh; Chakravarthy, Bheemisetty S; Narang, Manish; Mahantshetti, Niranjana S; Pandey, Anil Kumar
麻疹
免疫/内分泌
发表日期：2025
文献求助 收藏

Immunogenicity and safety of Biological E's CORBEVAX™ vaccine compared to COVISHIELD™ (ChAdOx1 nCoV-19) vaccine studied in a phase-3, single blind, multicentre, randomized clinical trial

在一项3期单盲、多中心、随机临床试验中，对Biological E公司的CORBEVAX™疫苗与COVISHIELD™（ChAdOx1 nCoV-19）疫苗的免疫原性和安全性进行了比较研究。

期刊:Human Vaccines & Immunotherapeutics
影响因子:3.5
doi:10.1080/21645515.2023.2203632
Thuluva, Subhash; Paradkar, Vikram; Gunneri, SubbaReddy; Yerroju, Vijay; Mogulla, Rammohan; Suneetha, Pothakamuri Venkata; Turaga, Kishore; Kyasani, Mahesh; Manoharan, Senthil Kumar; Adabala, Srikanth; Sri Javvadi, Aditya; Medigeshi, Guruprasad; Singh, Janmejay; Shaman, Heena; Binayke, Akshay; Zaheer, Aymaan; Awasthi, Amit; Singh, Chandramani; Rao A, Venkateshwar; Basu, Indranil; Kumar, Khobragade Akash Ashok; Pandey, Anil Kumar
免疫/内分泌
发表日期：2023
文献求助 收藏

A phase II/III randomised, comparative study evaluating the safety and immunogenicity of Biological E's live, attenuated Measles-Rubella vaccine in 9-12 month old healthy infants

一项 II/III 期随机对照研究，评估 Biological E 公司生产的减毒活麻疹-风疹疫苗在 9-12 个月大的健康婴儿中的安全性和免疫原性。

期刊:Contemporary Clinical Trials Communications
影响因子:1.4
doi:10.1016/j.conctc.2023.101232
Thuluva, Subhash; Gunneri, SubbaReddy; Turaga, Kishore; Mogulla, Rammohan Reddy; Yerroju, Vijay; Peta, Kalyankumar; Suneetha, Pothakamuri Venkata; Matur, Ramesh V
麻疹
免疫/内分泌
发表日期：2023
文献求助 收藏